[A16-19] Fingolimod (new therapeutic indication) - Addendum to Commission A15-48
Last updated 19.05.2016
Commission awarded on 12.04.2016 by the Federal Joint Committee (G-BA).
Head and nerves
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A15-48||Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2016-05-19 A G-BA decision was published.